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Abstract
The occurrence of metastasis is an important feature in cancer development.
In order to have a one-site model taking into account the interactions between
host, effector immune and tumor cells which is not only valid for the early
stages of tumor growth, we developed in this paper a new model where
are incorporated interactions of these three cell populations with endothelial
cells. These latter cells are responsible for the neo-vascularization of the
tumor site which allows the migration of tumor cells to distant sites. It is
then shown that, for some parameter values, the resulting model for the four
cell populations reproduces the angiogenic switch, that is, the transition from
avascular to vascular tumor.
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1. Introduction
Tumor growth is a complex process depending on various cell types as
mutant (tumor) cells, host (normal-tissue) cells, immune cells (lymphocytes,
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macrophages), endothelial cells... In order to get real insights into critical
parameters that control system dynamics, theoretical models are required
[1]. They can also be used for designing new effective treatments without an
extensive experimentation [2]. Typically, there are three levels for describing
interactions among these cells, namely the cell-, tissue- and organ-level. At
the individual-cell level, the complexity of the model increases in proportion
to the number of specific cells which contribute to the tumor growth. These
models are well suited for investigating in details a particular mechanism aris-
ing in a specific cancer. For instance, such an approach was used to describe
the role of the Adenosine TriPhosphate (ATP) metabolism as the cellular
energy carrier in tumor angiogenesis [3]: the corresponding cell energetics
model is made of three ordinary differential equations. The ATP is thus
used to drive a second model — at the tissue level — for tumor growth made
of three other ordinary differential equations governing tumor mass, imma-
ture vascular endothelial cell mass and total microvessel length; the model
depends on twenty-three parameters. Such a model type is necessarily spe-
cific to a given type of cancer since based on a description of interactions
at the cell level. In order to have a generic model, the tissue level was here
retained for modelling the tumor growth. This level of description was re-
quired to reduce the model complexity, thus avoiding a model too difficult
to parametrize and to investigate [4].
Indeed, most of the models used to investigate tumor growth are at the
tissue level as reviewed by Arujo and McElwain [5] or by Eftimie and co-
workers [4]: at this level of description unavoidable simplifications are made,
focusing on some detailed mechanisms depending on the objectives. Most of
the models are devoted to the interactions between tumor cells and immune
cells [4]. For a generic description of interactions between tumor and immune
cells, the number of ordinary differential equations is at least two [6, 7, 8].
Some specifications are developed for designing therapies in particular con-
texts for which specific cell types can be taken into account, thus increasing
the model dimension [9, 10, 11]. Thus, a set of 11 ordinary differential equa-
tions can be obtained [12]. In these cases, models are specific to a given type
of cancer. One of them was for instance developed for malignant melanoma
[13] by taking into account tumor cells, healthy cells, tumor angiogenic fac-
tor, blood vessel endothelial cells, necrotic debris, spatial pressure of oxygen
and basement membrane: this model is made of partial differential equations
for describing the spatial tumor growth as well as tumor angiogenesis. There
are also some models combining a tissue-level description with some migra-
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tions among various organs to take into account the circulating endothelial
progenitor cells [14] since these cells may contribute to tumor angiogenesis
[15].
In our cases, we would like to develop a generic model (not specific to a
given type of cancer) at the tissue level for a single tumor site, that is, ignoring
for now the diffusion process. Our aim is to include the micro-environment
(host or healthy cells) of the tumor cells as considered in [16] or in [17]. To
overcome the limitation of these latter models which are only for avascular
tumor growth, we introduced interactions between tumor, immune, host and
endothelial cells as recommended by Merlo and co-workers [18]. Since we
limit ourselves our model to a single tumor site, cell migration by diffusion
or by circulating through the blood vessels is not considered in this paper.
Nevertheless, we would like to have a model for which the presence (or not) of
angiogenesis depends in a simple way on some parameters since angiogenesis
is a relevant requirement for an expanding growth of multiple solid tumors
[19]. The angiogenic switch is a fundamental step which allows a tumor
whose size is less than 3 mm to switch from an avascular type (with a slow
growth) to a vascular type through new blood vessels under the influence
Tumor Angiogenesis Factor (TAF) like Vascular Endothelial Growth Factor
(VEGF) produced by tumor cells. The new vessels allow the tumor to get
a faster growth and to become more invasive [20]. The next step is the
acquisition of a metastatic phenotype [21] according to which cancer cells
use neo-vessels to migrate at a significant distance from the initial tumor
site, most often in other organs, to create new tumor sites [22, 23]. Thus
by introducing endothelial cells in the model initially proposed by de Pillis
and Radunskaya [24, 25] we constructed a one-site cancer model which is
also valid for vascular tumor growth. As performed in these works, we do
not consider cellular interactions at the molecular level, such an approach
necessarily leading to too complex models for simulating tumor growth at
the organ level as we planed to do in further works.
Most of cancer models do not describe the interactions between tumor
cells and the organism (the host cells). Among the very few models dealing
with host cells [16, 26, 27, 28] is the three-dimensional cancer model proposed
by de Pillis and Radunskaya [24, 25] which retained our attention as explained
below. It describes the interactions between tumor, immune and host cells. A
chaotic regime was observed in this model [29] and some bifurcation diagrams
were investigated in [30]. Some clinical evidences were well reproduced by
this model [24, 30, 31, 32]. In this latter study, it was shown that this model
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produces stiff oscillations of the population of tumor cells, corresponding to
a fast-growing cancer after a quite long period of latency: it corresponds to
tumor dormancy as discussed in [24]. We investigated this model using an
observability analysis which consists in determining whether a given variable
provides all the required information to distinguish states which are different
in the original phase space. This is performed by investigating the property
of the jacobian matrix of the coordinate transformation between the original
phase space and the space reconstructed by using successive time derivatives
of a given variable [33, 34]. Such an observability analysis of this cancer
model showed that if one would like to investigate the dynamics of the system
“tumor + organism”, it would be better to “measure” the number of host cells
[30]. It is rather hard to imagine how one could measure the number of host
cells since all cells in the body can be considered as host cells but transposed
to the clinical point of view, the host dynamics can be evaluated at the body
level by the tumor-induced symptoms. For instance, if the population of host
cells decreases, the tumor grows in size and symptoms appear. In the case
of patients who received treatments for a lung cancer, we thus designed a
follow-up based on weekly self-assessed symptoms (lack of apetite, fatigue,
pain, cough, breathlessness) and weight to “evaluate” the environment (host
cells) of the tumor: the reliability of such a follow-up is equivalent to those
of a routine imaging [35, 36].
Before considering spatio-temporal models for tumor growth, it is rele-
vant to have a model which reproduces the angiogenic switch, an important
feature inducing metastasis during tumor growth. It is therefore needed to
introduce endothelial cells in the three-dimensional model proposed by de
Pillis and Radunskaya. The subsequent part of this paper is organized as
follows. Section 2 briefly introduces the three-dimensional model describing
the interactions between host, immune and tumor cells. Section 3 briefly
describes the dynamics in the “tumor-free-limit”, that is, when there is no
tumor cell in the site. Section 4 is devoted to the interactions between these
first three types of cells with endothelial cells. A dynamical analysis of the
resulting four-dimensional model is then performed. Section 5 gives some
conclusions.
2. Three-dimensional cancer model
Mathematical cancer model taking into account normal (non malignant)
cells interacting with immune and tumor cells are not numerous. There is one
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proposed by Owen & Sheratt [16] which remains mainly focused on tumor-
macrophage interactions, the normal cells being only considered for their
ability to colonize the site studied. Some others only focused on tumor-host
interactions [26, 27, 28]. An interesting model by de Pillis and Radunskaya
[24, 25] incorporates host (normal), immune and tumor cells to reproduce
certain qualitative aspects as ocillations in tumor size (Jeff’s phenomenon)
[37] or tumor dormancy [38]. This model is rather generic in the sense that it
is not specific to a given type of cancer. It is indeed based on quite common
interactions between host, immune and tumor cells. The model is









Ṅ = ρ2N(1− b2N)− c4TN
Ṫ = ρ1T (1− b1T )− c2IT − c3TN
İ = s+
ρIT
α + T
− c1IT − d1I
(1)
where N represents the population of normal (host) cells, T the population
of tumor cells and I the population of immune cells. In this model, immune
cells can be B- or cytotoxic T- lymphocytes, or even Natural Killer. This is
a single tumor-site model where immune cells are considered as arising from
outside at a constant rate s as in an immunotherapy [39, 40]. Since we are
not considering such a case, we set s = 0.
System (1) can be thus rewritten in the dimensionless form






ẋ = ρ1x(1− x)− α13xz
ẏ =
ρ2yz
1 + z
− α23yz − δ2y
ż = ρ3z(1− z)− α31zx − α32zy
(2)
by using the coordinate transformation (N, T, I) 7→ (x, z, y). Thus, x desig-
nates the normalized population of host cells, y being the population of ef-
fector immune cells and z the population of tumor cells. Model (2) describes
interactions between these three populations as being mainly in competition
(Fig. 1). Tumor cells compete for resources with the two other populations
of cells. From that point of view, they are the “generalist” competitors while
the two others are “specific competitors”.
System (2) was investigated for the set of parameter values as follows.
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Figure 1: Flow graph for the 3D model proposed by de Pillis and Radunskaya describing
interactions between host, immune and tumor cells.
ρ1 = 0.518 host cell growth rate;
α13 = 1.5 host cell killing rate by tumor cells;
ρ2 = 4.5 effector immune cell growth rate;
α23 = 0.2 effector immune cell inhibition rate by tumor cells;
δ2 = 0.5 effector immune cell natural death rate;
ρ3 = 1 tumor growth rate;
α31 = 1 tumor killing rate by host cells;
α32 = 2.5 tumor cell killing rate by effector immune cells.
A previous study investigated in details the dynamics of this three-dimensional
system [30]. With the help of bifurcation diagrams, it was shown, for in-
stance, that increasing the growth rate ρ1 of host cells reduces the probability
for observing a large population of tumor cells. Nevertheless, when ρ1 was
large, the maximum of the latter population was nearly 1 and, when it oc-
curred, the tumor growth was very fast, as in these cancers with a very rapid
progression that leaves treatment inefficient. Another interesting result was
that the tumor cell killing rate α32 by the effector immune cells had no influ-
ence on the dynamics (it only needed to be non-zero), explaining why most
of the therapy acting on the immune system are not very efficient [41, 42].
With the above parameter values, a chaotic attractor characterized by
a smooth unimodal map was observed (Fig. 2). The smooth character of
this map is a signature of the period-doubling cascade observed as the route
to chaos [30]. A topological analysis lead to the template shown in Fig. 3
where each branch is associated with one of the monotonic branches in the
first-return map. The branch without half-turn corresponds to the increasing
branch labelled by “0” and the second branch of the template, with a negative
half-turn, is associated with the decreasing branch of the first-return map
(symbol “1”) (see [43, 44] for a detailed discussion of the topological analysis).
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Figure 2: Chaotic behavior solution to the 3D model as investigated in [30]. Parameter
values as in the main text.
3. Dynamics in the “tumor-free” limit
The purpose of this section is to check that when there is no tumor cell, the
dynamics of the model settles down onto a state which corresponds to a site
only made of host cells. When there is no tumor cell, the three-dimensional
model reduces to the two-dimensional system
{
ẋ = ρ1x(1− x)
ẏ = −δ2y
(3)
which has two fixed points
S0 =
∣
∣
∣
∣
0
0
and S1 =
∣
∣
∣
∣
1
0 .
(4)
The fixed point S0 corresponds to an empty site (without biological meaning).
Its eigenvalues are
Λ0 =
∣
∣
∣
∣
0.518
−0.5 .
(5)
It is therefore a saddle point, that is, an empty site is thus never observed
(the corresponding fixed point being unstable). The second fixed point has
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Figure 3: Template synthesizing the topology of the chaotic attractor (Fig. 2a) solution
to the 3D model (2).
two negative eigenvalues
Λ1 =
∣
∣
∣
∣
−0.518
−0.5 ,
(6)
inducing that this is a stable node point. Only initial conditions chosen in the
stable manifold of fixed point S0 induces a trajectory converging to that fixed
point. Consequently, almost all initial conditions from the positive quadrant
lead to a trajectory ending at this fixed point (Fig. 4).
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Figure 4: Phase portrait of the tumor free model (3). Only the host cells survive.
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4. A four-dimensional model with endothelial cells
In most of cancers, tissue invasion and the occurrence of metastasis is
a key step in tumor growth associated with a bad prognostic. Tumor cells
become thus more aggressive once tumor hypoxia triggered neo-vessels. In-
deed, beyond a given size, numerous tumor cells become in a state of hypoxia
and therefore trigger the tumor neo-angiogenesis, that is, induces the pro-
duction of new (blood and/or lymphatic) vessels issued from the existing
ones. Fed with supplementary resources, tumor cells proliferate with an
increased growth rate and neo-vascularization opens new routes for tissue in-
vasion and metastasis. This is the so-called angiogenic switch corresponding
to the switch from an avascular to a vascular tumor. Such an angiogenic
switch cannot exist without the endothelial cells that are responsible for the
production of vessels.
Our objective is thus to build a four-dimensional model able to repro-
duce the angiogenic switch by the means of endothelial cells. Three main
interactions have to be considered. The first type of interactions are between
tumor cells and endothelial cells. When the tumor diameter is less than 1
or 2 mm, tumor cell needs in oxygen and nutriments are satisfied by blood
vessels at a distance not exceeding 50-100 µm, that is, within the oxygen
diffusion distance. When the tumor size increases beyond this threshold,
tumor needs become too important and can no longer be satisfied by these
pre-existing blood vessels. Tumor cells must therefore drain oxygen and
nutriments from more distant locations, being beyond the oxygen diffusion
limit. Pushed to cellular hypoxia [45], tumor cells produce Hypoxia Inducible
Factor (HIF) proteins which stimulate in turn transcription of Vascular En-
dothelial Growth Factor genes. The newly produced VEGF protein binds to
VEGF receptors on endothelial cells producing vessels. Such a bind induces a
signal stimulating a proliferation of endothelial cells. It corresponds to arrow
1 drawn in the flow graph of our four-dimensional model (Fig. 5).
The second type of interactions involving the endothelial cells concerns
those with tumor cells. Once their growth is stimulated and that their migra-
tion is triggered, endothelial cells structure new blood vessels (in this model
we neglect the production of lymphatic vessels). New vessels thus reach the
neighborhood of tumor cells and, consequently, increase the proliferation of
the latter. In principle, new vasculature would not be selective in the types of
cells it provides nourishment and, consequently, it should also benefit to host
cells. Nevertheless, only tumor cells have the ability to migrate through neo-
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Figure 5: Flow graph of our four-dimensional model describing interactions between host,
effector immune, tumor and endothelial cells.
vessels and to proliferate more importantly than host cells without saturating
the considered tumor site. For this reason, tumor cells are more dependent on
endothelial cells than host cells; we therefore neglected interactions between
endothelial cells and host cells.
The third type of interactions considered in our model is between endothe-
lial cells and effector immune cells. Once cancerogenesis is initiated, effector
immune cells become the main actors of the organism reaction against tumor
cells. To reach tumor cells, immune cells travel in blood vessels. Thus, the
vascular development in the neighborhood of the tumor also increases the
ability of immune cells to interact with tumor cells and, consequently, to im-
prove the response of the immune system against the cancer. Endothelial cells
secrete chemoattractant molecules attracting immune cells; thus an increase
of chemoattractant concentration induced by a growth of endothelial cells
induces an additional influx of immune cells to the tumor site [1, 2, 46, 49].
By the same time, endothelial cells may have a negative effect on immune
cells [46], a feature that we also took into account in our model by the indi-
rect effect endothelial cells have on immune cells via interactions these two
cell populations have with tumor cells. In turn, this decrease of immune
cells provokes an increase of the tumor cell population. Tumor can also in-
hibit immune response [47, 48]. Although an endogenous immune response to
cancer is observed in preclinical models and patients, such response is ineffec-
tive because tumors develop multiple resistance mechanisms, including local
immune suppression, induction of tolerance and, systemic dysfunction in T-
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cell signaling. Tumors can exploit different ways to actively evade immune
destruction, including endogenous “immune checkpoints” that normally ter-
minate immune response after antigen activation. Blockade of programmed
death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome
immune resistance. Thus, tumor-immune cell interactions (described by the
term α23yz in our model) reinforce the negative impact of tumor cells on
immune cells whose population thus decreases.
Since our main objective is to obtain a cancer model reproducing the
tumor neo-angiogenesis, we focused our attention on the previous three types
of interactions. Other interactions between endothelial cells and host cells or
effector immune cells are not relevant in the context of the present model. For
instance, we assume that immune cells have no (or a very limited) impact on
the development of endothelial cells as done in [50]. More importantly, there
is no positive feedback loop of endothelial cells to themselves because their
development essentially results from the interactions they have with tumor
cells. Consequently, proliferation of endothelial cells is due, in our model, to
a coupling between tumor cells and endothelial cells associated with a small
natural death rate represented by a negative feedback loop.
4.1. The equations and a fixed point stability analysis
According to the flow graph, and based on the three-dimensional model
(2), we built a set of four differential equations describing the tumor growth
taking into account endothelial cells. The 4D model reads
















ẋ = ρ1x(1− x)− α13xz
ẏ =
ρ2yz
1 + z
− α23yz − δ2y + α24yw
ż = ρ3z(1 − z)− α31zx− α32zy +
α34zw
1 + w
ẇ =
ρ4wz
1 + z
− δ4w
(7)
where x represents the population of host cells, y is associated with the
population of effector immune cells, z with tumor cells and w corresponds to
endothelial cells.
Lymphocytes of the immune system circulate continuously between lymph
and blood. When an immune response is triggered, effector lymphocytes
reach the pathogen site (the tumor) via the blood flow. In other words, effec-
tor immune cells use vessels for their migration. Consequently, immune cells
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are thus promoted by endothelial cells contributing to new vessels through
which they can reach the tumor [46]. If immune cells do not require endothe-
lial cells to proliferate, the immune response is obviously stronger when they
are present. This positive interaction is represented by the sole term α24yw
in the second equation of model (7). We assumed that immune cells have no
impact on endothelial cells as it was done in [50].
Tumor cells interact with endothelial cells in a reciprocal manner, that is,
both types of cells receive benefits from their interactions. When tumor cells
are in hypoxia they produce pro-angiogenic factors whose most important is
the VEGF. These molecules bind to receptors at the endothelial cell surface,
thus leading to proliferation and migration of endothelial cells according to
the gradient of pro-angiogenic factor concentration ; endothelial cells are thus
attracted by tumor cells. At the cellular level, the presence of tumor cells
in the environment triggers the endothelial cell proliferation. At the tissue
level, such a feature can be described by a Michaelis-Menten term such as
ρ4wz
1+z
in the fourth equation of model (7); the population of endothelial cells
thus saturates at the maximal value ρ4. When new vessels are formed, tumor
cells are no longer in hypoxia and their proliferation is increased: this is the
so-called angiogenic switch leading to the vascular phase. A term reflecting
the proliferation of tumor cells due to the presence of endothelial cells is thus
added to the logistic term modelling the tumor cell growth. In the third
equation of model (7) we choose to represent this additional term by α34zw
1+w
as done for describing the proliferation of endothelial cells.
Both are type ii Holling response functions whose saturation effects are
more adequate to model these interactions than a type i Holling response
function. To complete this cancer model, the term −δ4w in the fourth equa-
tion describes the natural death rate of endothelial cells.
Our 4D model (7) is investigated with parameter values as
α24 = 0.3 stimulation of effector immune cells by endothelial cells;
α34 = 0.75 tumor cell growth rate due to neo-angiogenesis;
ρ4 = 0.86 endothelial cell growth rate;
δ4 =
1
11
endothelial cell natural death rate,
the other parameters being kept as for the 3D model. These parameter values
were chosen because they correspond to a chaotic attractor which is very
often observed when parameter values are varied. As for most mathematical
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models at tissue level, their biological meaning remains uncertain. These non
specific parameter values are useful for investigating the qualitative dynamics
of tumor growth as performed in [17]. What is relevant is how a change in
parameter values affects the dynamics. This will be investigated using some
bifurcation diagrams in the subsequent part of this paper.
With these parameter values, the 4D model (7) has seven fixed points
with positive coordinates, namely
• S0 =
∣
∣
∣
∣
∣
∣
∣
∣
0
0
0
0
,
• S1 =
∣
∣
∣
∣
∣
∣
∣
∣
1
0
0
0
,
• S2 =
∣
∣
∣
∣
∣
∣
∣
∣
0
0
1
0
,
• S3 =
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
0
y3 = 0.394
δ4
ρ4 − δ4
= 0.118
1
α24
[
δ2 −
1
ρ4 − δ4
(
δ4(ρ2 − α23)−
ρ2 δ
2
4
ρ4
)]
= 0.160
,
• S4 =
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
0
ρ3 − ξ
α23
= 0.347
ξ = 0.133
0
,
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• S5 =
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
1−
α13
ρ1
ξ = 0.616
ρ1ρ3(1− ξ)− α31 (ρ1 − α13ξ)
α32ρ1
= 0.101
ξ = 0.133
0
,
• S6 =
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
∣
1−
α13δ4
ρ1(δ4 − ρ4)
= 0.658
y6 = 0.131
δ4
ρ4 − δ4
= 0.118
1
α24
[
δ2 −
δ4 [ρ2(δ4 − 1)]
δ4 − ρ4
+
α23
ρ4(δ4 − ρ4)
]
= 0.160
,
where
ξ =
(ρ2 − α23 − δ2)−
√
(ρ2 − α23 − δ2)
2 − 4α23δ2
2α23
,
y3 and y6 being too complicated to be explicitely reported. The numerical
values here provided correspond to the parameter values previously given.
The first two fixed points correspond to the two fixed points obtained in the
tumor-free limit investigated in Section 3. There are also four fixed points
which have at least one negative coordinates; they do not contribute to the
dynamics since they are not located in the positive domain of the phase space
(a population cannot be negative).
• Point S0, located at the origin of the phase space, corresponds to an
empty site. As for the tumor-free limit, this point must be unstable
(since it has not biological meaning, it should not be possible to observe
it).
• Point S1 is associated with a site only inhabited by host cells whose
growth is governed by the logistic function ρ1x(1−x) (also observed in
the tumor-free limit). It should be stable, at least for healthy patients.
• Point S2 corresponds to a site where only tumor cells are observed with
the growth according to ρ3z(1 − z). This is thus a pathological state
for which tumor cells are at hypoxia: it must be unstable by definition.
14
• Contrary to this, point S3 corresponds to a site where tumor cells are
at equilibrium with effector immune and endothelial cells: it can be
stable, a property which would be of a worse prognostic for the patient
than point S2 since tumor cells can migrate to other sites due to new
blood vessels produced by endothelial cells.
• Point S4 is associated with a site inhabited by immune and tumor
cells: a priori, this point corresponds to an avascular tumor which
cannot induce metastasis since there is no endothelial cell involved.
The tumor should remain localized and, consequently, could be quite
well-treated by a radiotherapy, for instance.
• Point S5 corresponds to a site where host, immune and tumor cells
co-exist: such a state could be associated with a tumor before the
angiogenic switch occurs. Host cells are still dominant. The existence of
such a point reveals that, in certain cases, rare if this point is unstable, a
tumor does not necessarily increase its size up to the angiogenic switch.
• Point S6 represents a site in which the four populations co-exist, mean-
ing that the angiogenic switch already occurred: this is therefore a
vascular tumor. At such a point, the prognostic for the patient would
be uncertain since metastasis are very likely expected.
The stability analysis is performed using the jacobian matrix
J =













ρ1(1− 2x)− 1.5z 0 −1.5x 0
0 ρ2z
1+z
− 0.2z ρ2y
1+z
− ρ2yz
(1+z)2
0.3y
−0.5 + 0.3w −0.2y
−z −2.5z 1− 2z − x 0.75z
1−w
− 0.75zw
(1+w)2
−2.5y + 0.75w
1+w
0 0 ρ4w
1+z
− ρ4wz
(1+z)2
ρ4z
1+z
− 1
11













whose eigenvalues are
Λ0 =
∣
∣
∣
∣
∣
∣
∣
∣
−0.5
−0.09
ρ1 = 0.52
1
, Λ1 =
∣
∣
∣
∣
∣
∣
∣
∣
−ρ1 = −0.52
−0.5
−0.09
0
, Λ2 =
∣
∣
∣
∣
∣
∣
∣
∣
−1
ρ1 − 1.5 = −0.98
0.5ρ4 − 0.091 = 0.34
0.5ρ2 − 0.7 = 1.55
,
15
Λ3 =
∣
∣
∣
∣
∣
∣
λ2 = −0.01
−0.054± 0.62i
ρ1 − 0.177 = 0.34
, Λ4 =
∣
∣
∣
∣
∣
∣
−0.07± 0.61i
λ1 = 0.01
ρ1 − 0.199 = 0.32
,
Λ5 =
∣
∣
∣
∣
∣
∣
−0.52
λ1 = 0.01
0.04± 0.26i
, Λ6 =
∣
∣
∣
∣
∣
∣
−0.52
λ2 = −0.01
0.04± 0.29i
where the dependence of the eigenvalues on the three parameters ρ1, ρ2 and
ρ4 is explicitely provided when it is simple. λ1 and λ2 are solutions to a
fourth-degree polynomial.
The point S0 is a saddle point (thus unstable). Point S1 is nearly a stable
node: only one eigenvalue is null, inducing a marginal stability. Point S2 is a
saddle and unstable, confirming that a site cannot remain too long without
host cells. Fixed point S3, corresponding to a vascular tumor, is a saddle-
focus SF− with a 1D unstable manifold. Fixed point S4 associated with an
avascular tumor is a saddle-focus SF− with a two-dimensional unstable mani-
fold. Point S5, corresponding to a site where tumor cells do not interact with
endothelial cells, is a saddle-focus SF+, the two complex conjugated eigen-
values spanning the 3D unstable manifold with the positive real eigenvalue.
The last fixed point, S6, is also a saddle-focus SF+ with a 2D unstable man-
ifold. These four latter fixed points are connected by pairs, namely, S3-S5
and S4-S6. This could be a signature of some heteroclinic connections, one
between S3 and S5, and one between S4 and S6: such connections would be
the main “axis” around which the attractor would be structured as shown in
Fig. 6 (a feature which remains to further investigate).
We are now investigating how eigenvalues λ1 and λ2, both being real,
change their sign under limited parameter value variations. The first eigen-
value
λ1 = −2δ4 +
ρ4
2ρ2
(ρ2 + δ2 − α23 − ξ) (8)
only depends on parameters ρ2, ρ4, δ2, δ4 and α23. The second eigenvalue
λ2 is too complicated to be explicitely provided (its expression exceeded the
Maple R© capacity). We thus restrict our investigations by varying these five
parameter values, one by one, the others being kept as previsously given.
Our results are thus valid for a certain domain of the parameter space which
remains to be bounded (postponed for future works).
The sign of λ1 changes when ρ4 = ρ4 = 0.777 or ρ2 = ρ2 = 4.9536,
the other parameter values being kept as previously mentioned; it does not
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depend on ρ1. This bifurcation only affects the dimensionality of the stable
(unstable) manifold by ±1, but not the type of the concerned fixed points
which remain of the saddle type. When initial conditions are taken in the
neighborhood of S3 for instance, the population of endothelial cells remains
very small if not zero for ρ4 < ρ4; contrary to this, the population quickly
increases from any conditions in the neighborhood of S3 for ρ4 > ρ4. This
bifurcation has thus a relevant impact on the dimensionality of the chaotic
attractor as discussed in the subsequent part of this paper. The eigenvalues
λ2 change their sign when ρ4 = 0.9627, that is, for ρ4 > ρ∞ = 0.92 for
which the trajectory is ejected to infinity as discussed below. This second
bifurcation has therefore no impact on tumor growth.
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Figure 6: Chaotic attractor solution to the four-dimensional model (7). Fixed points
structuring the attractor are also shown. Parameter values as in the main text. In the
z-w plane projection, the axis joining S5 to S6 is shown to structure the folding of the
attractor.
4.2. Dynamical analysis
In order to perform the dynamical analysis, we choose to use the four dif-
ferential embeddings induced by each variable of our four-dimensional model.
Let us designate by s the “measured” variable. The corresponding differential
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embedding is thus spanned by







X = s
Y = ṡ
Z = s̈
W =
...
s .
(9)
The four X-Y plane projections corresponding to the attractors shown in
Figs. 6 are shown in Figs. 7. As for the 3D model (see a detailed discussion
in [30]), the differential embedding induced by variable x is the single one
which does not present a domain of the phase space where the trajectories
are strongly confined, meaning that host cells should still provide the best
observability of the dynamics (Fig. 11a).
In order to browse various patient conditions, we choose to vary two pa-
rameter values, namely the growth rate ρ1 of host cells since we observed that
it allows to switch from a common to a dormant cancer [30], and parameters
ρ2, ρ4, δ2, δ4 and α23 as previously discussed. Bifurcation diagrams versus
one of these parameters are computed as introduced in [30], that is, using
minima and maxima of a given variable to obtain its range of variability.
This is easily done in a differentiable embedding by defining the “double”
Poincaré section as
PD ≡
{
(Xn, Zn,Wn) ∈ R
3 | Yn = 0, Zn ≷ 0
}
(10)
where Zn > 0 corresponds to minima and Zn < 0 to maxima of the “mea-
sured” variable. The bifurcation diagrams versus the endothelial cell growth
rate ρ4 are shown in Figs. 8a-8c. They are terminated at ρ4 = ρ∞ ≈ 0.92,
when the trajectory is ejected to infinity. The most remarkable feature is
that there is a threshold value ρ4 = 0.777 under which there is no bifurca-
tion, thus meaning that this growth rate does not affect the dynamics (the
tumor growth) when ρ4 < ρ4: there is thus a range of “patient conditions” for
which the tumor growth does not depend on the endothelial cell growth rate,
and which corresponds to non metastatic patients. Beyond the threshold
value ρ4, the population of endothelial cells starts to be significantly differ-
ent from zero and presents chaotic oscillations as the others (Fig. 8c). A
patient with an endothelial cell growth rate greater than ρ4 could present a
neo-vascularized tumor as discussed below. To this bifurcation corresponds a
threshold value ρ4 beyond which the angiogenic switch we wanted to describe
with our model can be observed. As a consequence, the tumor site can be
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Figure 7: Differential embeddings induced by each variable of the 4D model. ρ4 = 0.86
and other parameter values as previously reported.
considered as being avascular when ρ4 < ρ4 and vascular otherwise. This
means that when the vascularization is large enough (ρ4 ≥ 0.9), tumor cells
saturate the site and start to migrate toward other sites leading to metastasis
which are therefore strongly governed by the endothelial cell growth rate. If
other parameter values are kept constant, there are thus two different groups
of patients, one with a growth rate ρ4 less than the threshold value and for
which patients do not present vascular tumor, and one with a growth rate
greater than the threshold value, leading to vascular tumor. It is clear that
this threshold value depends on the other parameter values, that is, on other
patient conditions.
From a dynamical point of view, this means that for ρ4 < ρ4, the chaotic
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Figure 8: Bifurcation diagrams versus the endothelial cell growth rate ρ4 (ρ2 = 4.5) and
versus the immune cell growth rate ρ2 (ρ4 = 0.86). Other parameters values as specified
for the other figures.
attractor can be embedded in the three-dimensional sub-space R3(x, y, z)
since w = 0. The first-return map to a Poincaré section built from the minima
of variable x (Fig. 11b) is a smooth unimodal map exactly as observed in
the 3D model for the same parameters value (Fig. 2b). Consequently, this
attractor is topologically equivalent to the attractor (Fig. 2a) solution to the
3D model.
Similar conclusions can be adressed when the immune cell growth rate ρ2
is decreased. For values larger than ρ2 = 4, 9536, the population of endothe-
lial cells remains very small. Below this threshold value, this population of
cells start to grow and vascular tumor can be observed. When ρ2 ≤ 4.21,
the population of tumor cells becomes too large to remain in the same tumor
site and necessarily starts to migrate toward other sites. When the growth
of endothelial cells (immune cells) is too large (small), metastatic cancer can
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Figure 9: Bifurcation diagrams versus the immune cell death rate δ2 (δ4 = 1/11) and the
endothelial cell death rate δ4 (δ2 = 0.5). Other parameters values as specified for the other
figures.
be most likely expected. As show in Figs. 9, the natural death rate δi af-
fects the dynamics in an opposite way than the corresponding growth rate
ρi (i = (2, 4)). The other parameter values being kept as specified in the
beginning of this section, the bifurcation values are δ2 = δ2 = 0.4521 and
δ4 = δ4 = 0.1006, respectively. When parameter values are chosen as in Fig.
7 and α23 is varied, there is no possibility to obtain a bifurcation in such
a way that the population of endothelial cells remains at very small values.
For these conditions, only vascular tumors are observed. The population of
tumor cells saturates the site for α23 ≥ 0.38.
These five parameters affect the nature of different fixed points. The type
of points S4 and S5 is changed when ρ2, ρ4 or δ4 is varied; contrary to this,
their eigenvalues and, in particular, λ1 is nearly unchanged when δ1 or α23 is
varied. Parameter δ2 can induce a change in the sign of λ2, thus affecting the
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Figure 10: Bifurcation diagrams versus the immune cell inhibition rate by tumor cells α23.
Other parameters values as specified for the other figures.
type of points S3 and S6. No bifurcation was identified in these two latter
points when α23 was varied.
When the angiogenic switch can appear according to patient conditions
(for instance, if ρ2 < ρ2, ρ4 > ρ4, δ2 > δ2, or δ4 < δ4, the other parameter
values being kept as specified earlier), populations of host and tumor cells
increase. As imposed to our model, the population of host cells only slighly
increases, remaining below the carrying capacity of the site. Contrary to
this, the population of tumor cells can become larger than the one allowed
by the carrying capacity of the “isolated” site without supplementary blood
vessels (Fig. 8b). This is due to the fact that our model is a single site model.
With a site placed in larger environment, supplementary tumor cells would
have migrated toward sites through the blood vessels built by endothelial
cells. It is also important to note that the growth of tumor cells is not too
damaging for host cells, thanks to the additional ressources carried by new
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Figure 11: Chaotic regime observed for ρ4 = 0.72. Other parameter values as in Fig. 7.
blood vessels. All these features correspond to common biological evidences
which are qualitatively validating our four-dimensional model.
Clinically speaking, let us consider one patient characterized, from our
model point of view, by a given set of parameter values. It seems reasonable
to assume that a patient in stable conditions would present parameter values
constant in time. It is thus possible to imagine various scenarios, only de-
pending on patient conditions, that is, on its parameter values. Let us first
consider a patient with an endothelial growth rate ρ4 = 0.72 < ρ4, the other
parameter values being those previously reported. Assume that he has a tu-
mor site with very few tumor cells, thus corresponding to initial conditions as
x0 = 1, y0 = 0.01, z0 = 0.01 and, w0 = 0.01. Time series of cell populations
are shown in Fig. 12a. First, tumor cells quickly proliferate, soon followed by
a rapid growth of the population of effector immune cells, in reaction against
the cancer progression. During this first period of time, the population of
host cells decreases near zero, and there is a very light increase of endothelial
cells. Then, all these populations start to oscillate, excepted the population
of endothelial cells which tends to zero. A patient with such a tumor site
would never have metastasis as long as none of his parameters change in such
a way that the previously discussed bifurcation occurs. In the absence of any
therapy, all these parameters should not change significantly over the period
of time commonly considered when a tumor growth is clinically observed,
that is, over a few years.
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Figure 12: Time series of the four populations of cells produced by model (7). Other
parameter values as in Fig. 7. Initial conditions x0 = 1, y0 = 0.01, z0 = 0.01 and
w0 = 0.01.
Let us now take a second case for which the endothelial growth rate
ρ4 = 0.92 > ρ4 (Fig. 12b). From the same initial conditions as used in the
previous case, the time series in the first short period of time (t < 200 ar-
bitrary units of time) presented by populations of host, immune and tumor
cells are quite similar to those observed for ρ4 = 0.72: consequently, clinically
speaking, the early tumor progression (t < 200 arbitrary units of time) would
not be distinguished from the previous one. In fact, the main departure is
in the evolution of endothelial cells which are progressively increasing their
population up to be significant (the angiogenic switch already occured) and,
then to mainly affect the dynamics of immune and tumor cells. The popula-
tions of immune and endothelial cells present nearly synchronous oscillations
in response to those of tumor cells. Endothelial cells are now able to build
new blood vessels to drain supplementary resources, mostly for tumor cells,
in this site. As already mentioned, since our model kept the site isolated
from a larger environment, populations of immune and tumor cells become
greater than those allowed by the carrying capacity.
In the second case, the patient would have metastasis for t > 380 arbitrary
units of time. From the clinical point of view, what would help to predict
the occurrence of metastasis would be to investigate the ability of the patient
to produce new endothelial cells in response to the demand of tumor cells,
a parameter which is not clinically assessed and thus leaving the impression
that cancer progression is only governed by stochastic laws.
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For large values of ρ4, the topology of the attractor (Fig. 13a) is not so
different than the one obtained with a 3D model when ρ1 is increased [30]: a
third branch occurs in the first-return map to a Poincaré section (Fig. 13b).
The main departure is in the differential structure of the attractor as evi-
denced by the unusual shape of the map with its flat maximum and its very
stiff decreasing branch. Such a map is mainly organized around a period-one
orbit (corresponding to tumor oscillation with a moderate amplitude whose
neighborhood is the most often visited two or three times before wandering
in another neighborhood) and a period-two orbit with one large amplitude
tumor oscillation followed by one small amplitude oscillation (Fig. 13c). Nev-
ertheless, we should not forget that the dynamics observed in the isolated site
described by our 4D model should be, in principle, affected by interactions
with other sites, at least when some of the populations are beyond of the
carrying capacity.
As a last investigation, we computed bifurcation diagrams versus the
host cell growth rate ρ1 in two situations: below (ρ4 = 0.72) and beyond
(ρ4 = 0.92) the bifurcation (Figs. 14). As we previously explained, the
diagrams we obtained for ρ4 = 0.72 are similar to those obtained with the
3D model (see [30]). For ρ4 = 0.92, the diagrams are less developed than
for ρ4 < ρ4 (compare the diagrams shown in Figs. 14b to those shown in
Figs. 14a) and dormant cancer cannot be observed with such endothelial cell
growth rate. The growth rate ρ1 cannot be increased as done with ρ4 < ρ4,
the trajectory being ejected to infinity at ρ1 ≈ 0.52. Migration of immune
and tumor cells would appear for ρ1 = 0.47, the parameter value at which
tumor cells exceed the carrying capacity: such a migration thus explains why
dormant cancer is no longer possible, even for largest ρ1-value.
5. Conclusion
The 3D model proposed by de Pillis and Radunskaya is very interesting
in the fact that it takes into account interactions of immune and tumor cells
(two very often considered populations in cancer models) with host cells (very
rarely considered). Its study led us to observe behaviors which are consistent
to some clinical observations as, for instance, the fact that the tumor cell
killing rate by effector immune cells does not influence the dynamics until
it is different from zero and, that some fast growing tumor after dormant
cancer can be observed for some parameter values. Nevertheless, this was a
single tumor site model which was therefore not able to reproduce relevant
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Figure 13: Three branch chaotic attractor solution to the 4D model. ρ4 = 0.90 and other
parameter values as in previous figures.
phenomena as the occurrence of metastasis. In order to overcome such a
limitation, we introduced in this 3D model the population of endothelial cells.
Our 4D resulting model reproduces the angiogenic switch, a key phenomenon
for tissue invasion and the production of metastasis. This 4D model must
be considered as a prerequisite before considering a spatial model for tumor
growth.
Contrary to de Pillis and Radunskaya’s model which was limited to early
stage of tumor growth, our model thus spontaneously reproduces the an-
giogenic switch which characterizes some developed cancers. In the present
one tumor-site version, the population of tumor cells increases beyond the
carrying capacity: when it will be connected to other sites, this will be trans-
formed into a tumor-cell migration. Such a migration would thus result from
interactions between tumor cells and their microenvironment [51, 52]. Our
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Figure 14: Bifurcation diagrams versus the host cell growth rate ρ1. Other parameters
values as specified for the other figures.
model does not take into account the biological complexity of cancer (ge-
nomic instability, expression of a given inhibition factor, etc.) but focuses
on generic interactions between the different cell populations. It thus allows
to reproduce situations observed in vivo or in clinics, as for instance, more
or less long latence phases without metastasis as well as strongly invasive
tumors providing very quickly metastasis [53, 54].
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